Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University, Cancer Hospital & Institute, No. 52, Fucheng Road, Haidian District, Beijing 100142, China.
Med Oncol. 2013;30(3):604. doi: 10.1007/s12032-013-0604-x. Epub 2013 May 18.
The aim of this study was to investigate the associations between UDP-glucuronosyltransferase (UGT) 1A1 polymorphisms and irinotecan-induced toxicities in Chinese advanced colorectal cancer patients. The genotypes of UGT1A1 6 and UGT1A1 28 were analyzed by PCR amplification and Sanger sequencing in 276 advanced colorectal cancer patients receiving irinotecan-containing chemotherapy. The influences of UGT1A1 6/28 polymorphisms on severe diarrhea and neutropenia were analyzed. The overall incidence of UGT1A1 6 and UGT1A1 28 variants was 35.5 % (GA: 28.6 %; AA: 6.9 %) and 21.0 % (TA6/TA7: 19.9 %; TA7/TA7: 1.1 %) in our cohort, respectively. A total of 16 patients (5.8 %, 16/276) had severe diarrhea and 56 patients (20.3 %, 56/276) had severe neutropenia. Neither UGT1A1 6 nor UGT1A1 28 variants were associated with severe diarrhea; however, either UGT1A1 6 (P = 0.001) or UGT1A1 28 (P = 0.029) variants were significantly associated with severe neutropenia. No differences were found between severe toxicities and clinical response in this study. Compared to western countries, Chinese patients had a distinct frequency of UGT1A1 6 or UGT1A1 28 genotypes. Both UGT1A1 6 and UGT1A1 28 variants were closely associated with irinotecan-induced severe neutropenia, but not diarrhea.
本研究旨在探讨 UDP-葡萄糖醛酸转移酶(UGT)1A1 多态性与中国晚期结直肠癌患者伊立替康诱导毒性的关系。采用聚合酶链反应扩增和 Sanger 测序法对 276 例接受含伊立替康化疗的晚期结直肠癌患者的 UGT1A1 6 和 UGT1A1 28 基因型进行分析。分析 UGT1A1 6/28 多态性对严重腹泻和中性粒细胞减少症的影响。在本队列中,UGT1A1 6 和 UGT1A1 28 变异体的总发生率分别为 35.5%(GA:28.6%;AA:6.9%)和 21.0%(TA6/TA7:19.9%;TA7/TA7:1.1%)。共有 16 例患者(5.8%,16/276)发生严重腹泻,56 例患者(20.3%,56/276)发生严重中性粒细胞减少症。UGT1A1 6 或 UGT1A1 28 变异体均与严重腹泻无关;然而,UGT1A1 6(P=0.001)或 UGT1A1 28(P=0.029)变异体与严重中性粒细胞减少症显著相关。在本研究中,严重毒性与临床反应之间无差异。与西方国家相比,中国患者 UGT1A1 6 或 UGT1A1 28 基因型的频率明显不同。UGT1A1 6 和 UGT1A1 28 变异体均与伊立替康诱导的严重中性粒细胞减少症密切相关,但与腹泻无关。
Zhonghua Zhong Liu Za Zhi. 2018-8-23
Drug Metab Pharmacokinet. 2016-2
Cancer Chemother Pharmacol. 2017-7
World J Gastroenterol. 2012-12-7
Oncol Rev. 2025-5-13
Int J Mol Sci. 2020-4-20
Cancer Chemother Pharmacol. 2013-3-31
Cancer Chemother Pharmacol. 2010-10-19
Pharmacogenomics J. 2010-2-23